Clinical Trial Update: Dose Finding Study of CHF 4226 for Treating Patients With COPD [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding study evaluating CHF 4226 in chronic obstructive pulmonary disease has completed; sponsor is Chiesi Farmaceutici S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 4226

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED